予防ヘルスケアの世界市場（2025年～2032年）

世界の予防ヘルスケアの市場規模は、2024年に3,881億7,000万米ドルに達し、2032年には1兆1,616億5,000万米ドルに達すると予測され、予測期間2024年～2032年のCAGRは14.1%で成長する見通しです。

予防ヘルスケアとは、日常的にヘルスケアの検診を行い、あらゆる種類の疾病の発生を予防するために必要な措置を講じることを指します。成人では、糖尿病、心血管疾患、がんなどの早期スクリーニングが、小児では、ワクチン接種、新生児スクリーニング、遺伝性疾患の遺伝子検査などが主な予防ヘルスケアです。

市場力学：

促進要因と抑制要因

予防ヘルスケアにおける政府の取り組みと投資の増加

予防ヘルスケアの実践を促進するための世界各国の政府によるイニシアチブの高まりは、将来的に市場を大きく押し上げると予想されます。慢性疾患の有病率の上昇に伴い、全体的な経済的負担は治療医学の方が高くなるため、各国政府は予防医学に重点を移しつつあります。予防接種、公衆衛生モニタリング、疾病スクリーニングプログラム、早期診断、啓発キャンペーンなど、さまざまな予防ヘルスケア分野で投資が拡大しています。

例えば2024年、フランスのAIS（Agence de l'innovation en sante）は、予防ヘルスケアに関連する新規機器の開発やその他の研究活動を支援するため、1億7,000万ユーロ（1億8,000万米ドル）の投資を発表しました。AISは、子どもの健康、メンタルヘルス、不妊症、慢性疾患、感染症、希少疾患、依存症など8分野に焦点を当て、大規模プロジェクト、環境要因に関する研究プログラム、予防技術を開発する産業プロジェクトなど3つの開発分野に予算を割り当てています。

さらにGaviは、2026年～2030年の間に、Gaviとワクチンパートナーは巨額の投資により世界の予防接種プログラムを強化する計画であると述べています。この期間中、ワクチンアライアンスは、国内の共同出資と自己資金によるワクチンプログラムを通じて40億米ドルの資金貢献を行い、800万～900万人の命を救い、5億人の子どもに予防接種を行う計画です。

これらの投資は、公衆衛生の成果を大幅に改善し、疾病負担を軽減し、高額な治療や入院の必要性を減らすことができます。

予防ヘルスケア診療のコストが高いことが、市場の成長を抑制する可能性があります。

予防ヘルスケア対策は、特に自己負担が大きい場合、個人にとっては高額に感じるかもしれません。そのため、予防プログラムに積極的に参加したり、定期的に検診やスクリーニングを受けたりする意欲が失われる可能性があります。包括的な予防ヘルスケアプログラムの実施には、インフラ、技術、人材育成への多額の財政投資が必要となることが多くあります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 予防ヘルスケアにおける政府の取り組みと投資の増加
    • 予防ヘルスケアの認知度と実践の向上
    • 早期疾患スクリーニングのための技術革新
  • 抑制要因
    • 予防ヘルスケアの高コスト
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• 疫学
• 価格分析
• パイプライン分析
• 特許分析
• 規制分析

第6章 タイプ別

• 製品
• サービス

第7章 用途別

• 予防接種
  • 早期診断
    • がん
    • 糖尿病
    • 心血管疾患
    • 遺伝学的検査
    • 新生児スクリーニング
    • その他
• 健康モニタリング/スクリーニング
• コンディション管理
• その他

第8章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋
• 中東・アフリカ

第9章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第10章 企業プロファイル

• Pfizer Inc.
  • 会社概要
  • 製品ポートフォリオ
  • 財務概要
  • 主な発展
  • SWOT分析
• AstraZeneca
• GSK plc.
• Sanofi
• Merck & Co., Inc.
• Meridian Bioscience
• Exact Sciences Corporation.
• GRAIL, Inc.
• Myriad Genetics, Inc.
• Apple Inc.
• SAMSUNG
• Fitbit
• Bio-Rad Laboratories, Inc.
• Revvity
• Trivitron Healthcare

第11章 付録

The global preventive healthcare market reached US$ 388.17 billion in 2024 and is expected to reach US$ 1,161.65 billion by 2032, growing at a CAGR of 14.1% during the forecast period 2024-2032.

Preventive healthcare refers to the routine practice of healthcare checkups, and taking necessary measures to prevent the occurrence of any kind of disease. Among the adult population, preventive healthcare refers to early screening for conditions such as diabetes, cardiovascular diseases, cancers, etc, and among children, vaccination, newborn screening, genetic testing for inherited diseases, etc are the major preventive healthcare steps.

Market Dynamics: Drivers & Restraints

Rising government initiatives and investments in preventive healthcare

The rising initiatives by governments across the globe to promote the practice of preventive healthcare are expected to significantly boost the market in the future. With the rising prevalence of chronic conditions, the overall economic burden is higher for curative medicine, hence the governments are shifting their focus to preventive medicine. The investments are growing in various preventive healthcare sectors such as vaccinations, public health monitoring, disease screening programs, early-stage diagnostics, and awareness campaigns.

For instance, in 2024, Agence de l'innovation en sante, AIS of France announced an investment of €170 (~ US$180) million to support the development of novel devices and other research activities related to preventive healthcare. With a focus on eight fields such as children's health, mental health, infertility, chronic diseases, infectious disease, rare diseases, and addiction, AIS has allocated the budget for three development areas such as large-scale projects, a research program on environmental factors and industrial projects that develop preventive technologies.

Moreover, Gavi has stated that between the period of 2026-2030, Gavi and the vaccine partners plan to strengthen the global vaccination programs with huge investments. During the period, the vaccine alliance plans to save 8 to 9 million lives and immunize 500 million children through a financial contribution of US$ 4 billion through domestic co-financing and self-funded vaccine programs.

These investments can significantly improve public health outcomes, reduce the disease burden, reducing the need for expensive treatments and hospitalizations.

The high cost of preventive healthcare practices may restrain the market growth.

Individuals may find preventive healthcare measures expensive, especially if they have to bear the costs out-of-pocket. This can discourage people from actively participating in preventive programs or getting regular screenings and check-ups. Implementation of comprehensive preventive healthcare programs often requires substantial financial investments in infrastructure, technology, and personnel training.

Segment Analysis

The global preventive healthcare market is segmented based on type, application, and region.

Early-stage diagnostics in the application segment is expected to grow with the highest CAGR in the forecast period.

Early-stage diagnostics play a crucial role in preventive healthcare as they aid in the early detection of preventable diseases. Early-stage diagnosis refers to the identification of the disease risk and burden before the incidence of symptoms or in the initial stages. This can significantly reduce the disease and economic burden on the patient. There are several tools available for early-stage detection of various chronic and life-threatening diseases such as diabetes, heart stroke & other cardiovascular diseases, cancer, infectious diseases, etc. This early-stage detection allows for timely intervention before the disease incidence, and improve the overall patient outcome. The market for early-stage diagnostics is expected to significantly grow in the forecast period due to rising investments, launch of novel diagnostic tools and the increasing adoption rate by the population.

For instance, in December 2024, Strand Life Sciences, a subsidiary of Reliance Industries of India launched a new early cancer detection tool called CancerSpot. The test can detect multiple cancers from blood samples using Strand Life Science's proprietary sequencing technology. Moreover, in February 2024, All India Institute of Medical Sciences (AIIMS) Delhi launched a new Artificial Intelligence (AI) platform that enables the early detection of gynecological cancers.

Geographical Analysis

Asia-Pacific is expected to grow with the highest CAGR in the preventive healthcare market.

Asia-Pacific region is not only well known for its higher population but also for the advancing healthcare landscape. The growing elderly population and increasing prevalence of chronic non-communicable diseases are making the population highly aware of the importance of preventive measures. As per the World Health Organization statements 62% of all deaths in South East Asia are due to non-communicable diseases which account for 9 million persons. All these deaths could be avoided by the practice of preventive healthcare through early disease diagnosis, risk assessments, regular disease screening, health monitoring, etc. However, the practices of healthcare are rapidly changing in the region. The population of Asia-Pacific is rapidly becoming aware of the importance of preventive medicine. To further propel the practice, governments across the region are actively alocating budgets, launching screening programs, awareness campaigns for preventive healthcare.

For instance, for the financial year 2024-25, India's Ministry of Health and Family Welfare (MoHFW) has allocated a budget of Rs. 87,657 crores (~US$10.2 billion) for the for the Department of Health & Family Welfare (DoHFW). Moreover, Rs. 70,051 crore (~US$8.1 billion) grants for health through the local Governments were provided by the 15th Finance Commission. The health budget has seen a rise of 85% from the fiscal year 2017-18. In addition, till 10th December 2024, 1,75,418 Ayushman Arogya Mandirs (AAMs) have been established and operationalized whose function is to perform primary healthcare services including preventive medicine.

This huge makeshift in the healthcare practices in one of the fastest growing economies i.e., India reflects the region's investment in preventive healthcare.

Competitive Landscape

The major global players in the preventive healthcare market are Pfizer Inc., AstraZeneca, GSK plc., Sanofi, Merck & Co., Inc., Meridian Bioscience, Exact Sciences Corporation., GRAIL, Inc., Myriad Genetics, Inc., Apple Inc., SAMSUNG, Fitbit, Bio-Rad Laboratories, Inc., Revvity and Trivitron Healthcare among others.

Emerging Players

The emerging players in the preventive healthcare market include Chronomics Limited., CEREBRA.AI LTD, Aidoc, and iSchemaView, Inc. and ataraxis.ai, among others.

Key Developments

• In October 2024, ataraxis.ai launched a novel AI-powered diagnostic test called Ataraxis Breast for precise and early detection of breast cancer. This tool can help physicians to prescribe personalized treatment to the patient and significantly improve the overall clinical outcome.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing innovations, and novel platform developments and forecasts upcoming technological advancements.
• Type Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates user feedback and data into product/technology development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global preventive healthcare market report would provide approximately 69 tables, 48 figures, and 235 pages.

Target Audience 2023

• Manufacturers: Pharmaceutical, Biotech Companies, Tech Leaders.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: R&D Professionals, Tech Innovators, AI Professionals.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Type
• 3.2. Snippet by Application
• 3.3. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising government initiatives and investments in preventive healthcare
    • 4.1.1.2. Rising awareness and practices of preventive healthcare
    • 4.1.1.3. Technological innovations for early disease screening
  • 4.1.2. Restraints
    • 4.1.2.1. High cost of preventive healthcare
  • 4.1.3. Opportunities
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Epidemiology
• 5.3. Pricing Analysis
• 5.4. Pipeline Analysis
• 5.5. Patent Analysis
• 5.6. Regulatory Analysis

6. By Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 6.1.2. Market Attractiveness Index, By Type
• 6.2. Products*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Services

7. By Application

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 7.1.2. Market Attractiveness Index, By Application
• 7.2. Vaccination*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.2.3. Early-Stage Diagnostics
    • 7.2.3.1. Cancer
    • 7.2.3.2. Diabetes
    • 7.2.3.3. Cardiovascular Diseases
    • 7.2.3.4. Hereditary Testing
    • 7.2.3.5. New Born Screening
    • 7.2.3.6. Others
• 7.3. Health Monitoring/Screening
• 7.4. Condition Management
• 7.5. Others

8. By Region

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 8.1.2. Market Attractiveness Index, By Region
• 8.2. North America
  • 8.2.1. Introduction
  • 8.2.2. Key Region-Specific Dynamics
  • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.2.5.1. U.S.
    • 8.2.5.2. Canada
    • 8.2.5.3. Mexico
• 8.3. Europe
  • 8.3.1. Introduction
  • 8.3.2. Key Region-Specific Dynamics
  • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.3.5.1. Germany
    • 8.3.5.2. U.K.
    • 8.3.5.3. France
    • 8.3.5.4. Spain
    • 8.3.5.5. Italy
    • 8.3.5.6. Rest of Europe
• 8.4. South America
  • 8.4.1. Introduction
  • 8.4.2. Key Region-Specific Dynamics
  • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.4.5.1. Brazil
    • 8.4.5.2. Argentina
    • 8.4.5.3. Rest of South America
• 8.5. Asia-Pacific
  • 8.5.1. Introduction
  • 8.5.2. Key Region-Specific Dynamics
  • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.5.5.1. China
    • 8.5.5.2. India
    • 8.5.5.3. Japan
    • 8.5.5.4. South Korea
    • 8.5.5.5. Rest of Asia-Pacific
• 8.6. Middle East and Africa
  • 8.6.1. Introduction
  • 8.6.2. Key Region-Specific Dynamics
  • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

9. Competitive Landscape

• 9.1. Competitive Scenario
• 9.2. Market Positioning/Share Analysis
• 9.3. Mergers and Acquisitions Analysis

10. Company Profiles

Key Market Players

• 10.1. Pfizer Inc.*
  • 10.1.1. Company Overview
  • 10.1.2. Product Portfolio
  • 10.1.3. Financial Overview
  • 10.1.4. Key Developments
  • 10.1.5. SWOT Analysis
• 10.2. AstraZeneca
• 10.3. GSK plc.
• 10.4. Sanofi
• 10.5. Merck & Co., Inc.
• 10.6. Meridian Bioscience
• 10.7. Exact Sciences Corporation.
• 10.8. GRAIL, Inc.
• 10.9. Myriad Genetics, Inc.
• 10.10. Apple Inc.
• 10.11. SAMSUNG
• 10.12. Fitbit
• 10.13. Bio-Rad Laboratories, Inc.
• 10.14. Revvity
• 10.15. Trivitron Healthcare
• Similar data will be provided for each market player.

LIST NOT EXHAUSTIVE

11. Appendix

• 11.1. About Us and Services
• 11.2. Contact Us